Items Tagged ‘immunotherapy’

October 12th, 2017

Immunotherapy Active Against Triple-Negative Breast Cancer

By

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that they are estrogen-receptor negative (ER-), […]

View full entry

Tags: atezolizumab, Breast Cancer, checkpoint inhibitor, immunotherapy, keytruda, News, PD-1, pembrolizumab, Precision Cancer Medicine, Tecentriq, Triple Negative Breast Cancer


September 28th, 2017

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

By

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European Society for Medical Oncology and published simultaneously in the New England Journal of Medicine. There remains an unmet need for […]

View full entry

Tags: immunotherapy, ipilimumab, Melanoma, News, nivolumab, opdivo, Precision Cancer Medicine, Yervoy


September 25th, 2017

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns

By

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab) clinical studies to its growing list of clinical trials placed on partial hold over safety concerns while further […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, Multiple Myeloma, News, PD-1, PD-L1


September 18th, 2017

Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer

By

Keytruda (pembrolizumab) appears promising in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.1 Stomach cancer (gastric cancer), is the third leading cause of cancer-related deaths worldwide. Overall, the 5-year survival rate for patients with gastric cancer […]

View full entry

Tags: Gastric Cancer, immunotherapy, KEYNOTE-059 programmed death-ligand 1, keytruda, metastatic gastric cancer, News, PD-L1, pembrolizumab, Precision Cancer Medicine, stomach cancer


August 21st, 2017

U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial

By

CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has been removed and that all clinical trial activities under this Investigational New Drug application may resume. […]

View full entry

Tags: Head and Neck Cancer, immunotherapy, interleukin, Leukocyte, Multikine, News


July 24th, 2017

Penn Study Suggests that Combining CAR T Cells with Existing Immunotherapies May Overcome Resistance in Glioblastomas

By

Donald M. O’Rourke, MD Genetically modified “hunter” T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat […]

View full entry

Tags: Brain Cancer, brain tumor, CAR T Cells, glioblastoma, immunotherapy, News


July 11th, 2017

Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising

By

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking place June 28 through July 1, 2017 in Barcelona, Spain. AM0010 is being evaluated in an ongoing Phase 1/1b clinical trial that has enrolled 352 advanced cancer patients and in a […]

View full entry

Tags: AM0010, immunotherapy, Interleukin-10, News, Pancreatic Cancer, pegilodecakin


July 6th, 2017

First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients

By

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global team led by David Carbone, […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, keytruda, Lung Cancer, News, nivolumab, nsclc, opdivo, Precision Cancer Medicine


June 22nd, 2017

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer

By

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer (TNBC).  Overall patients with TNBC achieved a 71% pathologic complete response to the combination treatment in the […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, durvalumab, immunotherapy, News, precision medicine, Triple Negative Breast Cancer


June 15th, 2017

With Nearly Three Years of Follow-Up, Keytruda® Continues to have Improved Survival Benefit Compared to Yervoy® in Advanced Melanoma

By

Keytruda® (pembrolizumab) continues to outperform Yervoy® (ipilimumab) as initial treatment of patients with advanced melanoma. Updated results of the KEYNOTE 006 trial presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) report that Keytruda is now associated with a 30% improvement in survival when used as initial treatment for advanced […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, ipilimumab, KEYNOTE-006, keytruda, Melanoma, News, PD-1, pembrolizumab, precison medicine, Yervoy


June 2nd, 2017

Radiation Therapy can Enhance Effectiveness of Immunotherapy in People With Advanced Lung Cancer

By

UCLA RESEARCH ALERT FINDINGS A new study by UCLA scientists has found that the breakthrough immunotherapy drug Keytruda (pembrolizumb)  can be more effective in improving survival in people with non-small cell lung cancer (NSCLC) if they have previously received radiation therapy, compared to those without a history of radiation treatment. The findings are important as […]

View full entry

Tags: immunotherapy, Keyturda, Lung Cancer, Lung Cancer - Non-Small Cell, NCSLC, News, PD-1, pembrolizumb, radiation


May 11th, 2017

FDA Approves Imfinzi for Treatment of Urothelial Cancer

By

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of treatment with that chemotherapy. Bladder cancer is the most common type […]

View full entry

Tags: Bladder Cancer, durvalumab, Imfinzi, immunotherapy, News, PD-1, urothelial carcinoma


May 8th, 2017

First New Drug for Liver Cancer in a Decade: Stivarga

By

The US Food and Drug Administration (FDA) has expanded the indication for Stivarga (regorafenib) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug Nexavar. Expansion of Stivarga, ‘s indication marks the first FDA-approved treatment for a liver cancer in almost a decade. Stivarga is an oral […]

View full entry

Tags: immunotherapy, Liver Cancer, News, regorafenib, Stivarga


May 4th, 2017

Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma

By

Results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) were updated recently at the American Society of Hematology Annual Meeting in San Diego, California.  Overall 76% of patients with Diffuse Large B-Cell Lymphoma (DLBCL) responded to treatment, 47% achieving a complete remissions (CR). About axicabtagene ciloleucel Axicabtagene […]

View full entry

Tags: CAR T, HD, HNL, immunotherapy, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma


April 21st, 2017

Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed

By

Small, phase one trial of a dendritic cell vaccine supports further study in larger trials A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival increases, researchers at the Duke […]

View full entry

Tags: General, glioblastoma, immunotherapy, News, Other News Topics (not Types of Cancer)